About antibody-drug conjugates (ADC)

Antibody-drug conjugates (ADCs) are one of the fastest growing drug classes in oncology therapy. ADCs are composed of monoclonal antibodies (mAbs) (referred to as “Targeting Agent”) linked to cytotoxic drugs (also referred to as “Payload”) and are designed to improve the tumor reduction function of antineoplastic agents by targeted delivery to cells that express the specific target molecules, such as a target antigen of interest. A linker is typically positioned between the mAb and Payload for desired properties, such as stability, cleavage under proper conditions to release the Payload, and others.

ADCs have shown promising results in treating cancers, with about 15 drugs approved by the U.S. Food and Drug Administration (FDA) and dozens more currently in preclinical and clinical development.

We have made a significant advancement in the development of antibody drug conjugates, or ADCs, using our novel patented linker and payload platform technology. In preclinical studies, we observed our ADC to have better tumor size reduction over different tumors with a broad range of target antigens expression level compared with some of the best ADC benchmarks on the market in preclinical studies. In the meantime, ADCs honing to novel targets using our novel platform technology are also being prepared with the goal of generating leading candidates for clinical studies.